| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Mycophenolic acid (Mycophenolate) is an approved immunosuppressant drug used for preventing rejection in organ transplantation.It prevents an enzyme required for the development of T cells and B cells. To increase the orally bioavailable bioavailability, it was first marketed as the prodrug mycophenolate mofetil (MMF).
| Targets |
Microbial Metabolite; Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
Numerous RNA viruses, such as the hantavirus, rotavirus, CCHFV, dengue virus, influenza, and Zika virus, are susceptible to the antiviral actions of mycophenolic acid [1]. The virus's rate-limiting enzyme is called IMPDH. On endothelial cells and fibroblasts, de novo mycophenolate mofetil (0.01-1 μM; 72 hours) shows selective antiproliferative action. The most susceptible cells to mycophenolic acid therapy are endothelial cells, and the antimitotic action of this compound has an IC50 < synthesis [2]. In comparison to endothelial cells, fibroblasts have a greater IC50 (<1 μM) for mycophenolic acid-induced cell cycle inhibition. A549 non-small cell lung cancer cells, 500 nM, are two human tumor cell lines [2]. and PC3 cadavers had IC50 >1 μM and modest body weight. Up to 1 μM of MPA therapy does not affect U87 astrocytes [2]. Mycophenolic acid on HDAC2 (0.05–2 μM; 18 hours)
|
| ln Vivo |
Mycophenolic acid regulates the tumor microenvironment to greatly limit the formation of U87 tumors in BALB/c nude mice [2].
|
| Cell Assay |
cell proliferation assay [2]
Cell Types: primary isolated human dermal microvascular endothelial cells (HDMVEC), fibroblasts, U87 glioblastoma cells, PC3 prostate cancer In cells, A549 non- and MYC exhibit debt invoicing, which is upregulated by NDRG1[2]. Small cell lung cancer cells Tested Concentrations: 0.01, 0.1, 1 μM Incubation Duration: 72 hrs (hours) Experimental Results: demonstrated preferential anti-proliferative activity on HDMVEC and fibroblasts. U87 glioblastoma cells were resistant to treatment, whereas A549 non-small cell lung cancer and PC3 prostate cancer cells demonstrated intermediate sensitivity. Western Blot Analysis[2] Cell Types: HDMVEC Tested Concentrations: 0, 0.05, 0.1, 0.5, 1 and 2 μM Incubation Duration: 18 hrs (hours) Experimental Results: Shows dose-dependent regulation of HDAC2, MYC and NDRG1. |
| Animal Protocol |
Animal/Disease Models: Athymic 8weeks old, 20 g BALB/c nu/nu mycophenolic acid-bearing mouse drug-resistant human U87 tumor model [2]
Doses: 120 mg/kg MMF (mycophenolate mofetil prodrug) Mode of Route of Administration: po (oral gavage); bid Experimental Results: Compared with control mice, MMF (mycophenolate mofetil prodrug) Dramatically inhibited tumor growth in MMF-treated mice (approximately 14 days after tumor implantation) 70%). Microvessel density (CD31 staining) and pericyte coverage measured by α-smooth muscle actin staining were Dramatically diminished in MMF-treated tumors compared with control tumors (44% and 78%, respectively). |
| References |
[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255.
[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68. |
| Molecular Formula |
C23H31NO7
|
|---|---|
| Molecular Weight |
433.495
|
| Exact Mass |
433.21
|
| Elemental Analysis |
C, 63.73; H, 7.21; N, 3.23; O, 25.84
|
| CAS # |
24280-93-1
|
| Related CAS # |
Mycophenolic acid-d3;1185242-90-3;Mycophenolic acid sodium;37415-62-6;Mycophenolic acid-13C17;1202866-92-9
|
| Appearance |
Solid powder
|
| SMILES |
CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O
|
| InChi Key |
RTGDFNSFWBGLEC-SYZQJQIISA-N
|
| InChi Code |
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
|
| Chemical Name |
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
|
| Synonyms |
Mycophenolic acid; Mycophenolate mofetil; RS-61443; Myfortic; Cellcept
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~64 mg/mL (~199.8 mM)
Ethanol: ~32 mg/mL (~99.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 33.33 mg/mL (104.05 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3068 mL | 11.5340 mL | 23.0681 mL | |
| 5 mM | 0.4614 mL | 2.3068 mL | 4.6136 mL | |
| 10 mM | 0.2307 mL | 1.1534 mL | 2.3068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03899103 | Active Recruiting |
Drug: Mycophenolate Mofetil Drug: Rituximab |
Steroid-Dependent Nephrotic Syndrome |
Nilratan Sircar Medical College |
May 15, 2019 | Phase 3 |
| NCT03386539 | Active Recruiting |
Drug: Everolimus Drug: Tacrolimus |
Immunosuppression Heart Transplant Infection |
Boston Children's Hospital | January 29, 2018 | Phase 3 |
| NCT04669210 | Active Recruiting |
Drug: Ruxolitinib Drug: Tacrolimus |
Acute Myeloid Leukemia Acute Lymphoid Leukemia |
St. Petersburg State Pavlov Medical University |
November 3, 2020 | Phase 2 |
| NCT01428973 | Active Recruiting |
Drug: Sirolimus Drug: Mycophenolate mofetil |
Graft-Versus-Host Disease Hematological Malignancies |
University of Liege | September 2011 | Phase 2 |
| NCT04927390 | Active Recruiting |
Drug: Mycophenolate Mofetil 500mg |
Limited Cutaneous Systemic Sclerosis Systemic Sclerosis |
University College, London | December 8, 2021 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA